Rifampin-Induced Immune Hemolytic Anemia during Treatment of Pulmonary Tuberculosis in a Patient with Primary Sjogren's Syndrome

Jin-Woo SOUK; Yang-Ki KIM; Gae-Eil JANG; Hyun-Seok JEONG; Soo-Taek UH; Ki-Up KIM; So-My KOO; Bo-Young LEE; Hyunjin NOH; Woo-Yong SHIN; Jeong-Won SHIN; So-Young JIN.
Korean Journal of Blood Transfusion ; : 246-252, 2019.
Artículo en Ko | WPRIM | ID: wpr-917527

Documentos relacionados

  1. Efficacy and safety of rifampicin in patients with persistent hepatocellular secretory failure.
  2. [Drug-induced immune hemolytic anemia caused by cefmetazole].
  3. Protocol, rationale and design of BE-PEOPLE (Bedaquiline enhanced exposure prophylaxis for LEprosy in the Comoros): a cluster randomized trial on effectiveness of rifampicin and bedaquiline as post-exposure prophylaxis of leprosy contacts.
  4. Bedaquiline resistance probability to guide treatment decision making for rifampicin-resistant tuberculosis: insights from a qualitative study.
  5. [A Case of Intra-abdominal Tuberculosis Due to Mycobacterium bovis Mimicking Ovarian Cancer: Importance of Microbiological Diagnosis].
  6. Three different pathways of IgM-antibody-dependent hemolysis are mainly regulated by complement.
  7. Population pharmacokinetics analyses of rifampicin in adult and children populations: A systematic review.
  8. Anti-Ata in a renal transplant candidate: a case report.
  9. [Diagnosis and classification of direct antiglobulin test-negative autoimmune hemolytic anemia].
  10. Acute tubulointerstitial nephritis caused by rifampicin: An increasing and often overlooked side effect in elderly patients
.